# US 2023/0406945 A1 · ANTI-CD154 ANTIBODIES HAVING IMPAIRED FcR BINDING AND/OR COMPLEMENT BINDING PROPERTIES AND USE IN THERAPY

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0406945 A1
- Document ID: US20230406945A1
- Status: Published application
- Kind: A1
- Application number: 18/163,374
- Filed: 2023-02-02
- Published: 2023-12-21
- Earliest claimed: 2011-04-04
- Assignees: Trustees of Dartmouth College
- Applicants: The Trustees of Dartmouth College
- Inventors: Randolph J. Noelle
- Web page: https://patentgrep.com/patent/US20230406945A1

## CPC

- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C07K 16/18: against material from animals or humans
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/522: CH1 domain
- C07K 2317/524: CH2 domain
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Improved anti-CD154 antibodies are provided herein which have ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein.

## Claims

### Claim at position 1

1-26. (canceled)

### Claim 27

A method of inhibiting the activity of CD154 in a subject in need thereof which comprises the administration of a therapeutically effective amount of a anti-CD154 antibody of the human IgG1 isotype, comprising an Fc region which comprises an E269R mutation and a K322A mutation and which further comprises one additional Fc modification which impairs FcR binding and/or impairs complement binding, wherein said anti-CD154 antibody comprises the VL complementarity determining regions (CDRs) of SEQ ID NO: 17, 18, and 19 and the VL CDRs of SEQ ID NO: 24, 25 and 26 wherein the one additional Fc modification which impairs FcR binding is selected from the following mutations: E233P, D265A, D265N, D270N, N297A, S298N, P329A, D270A, K326V, V369R, F405K, L410P, V427R, L234N, G237M, S239F, V262E, V264F, V266T, S267N, N268E, N297R, T299A, R301D, N325L, N325E and L328R, and the additional Fc modification which impairs complement binding is a P331G or P331G/K322A mutation.

### Claim 28

An anti-CD154 antibody of the human IgG1 isotype, comprising an Fc region which comprises an E269R mutation and a K322A mutation and which further comprises an additional Fc modification which impairs FcR binding and/or impairs complement binding, wherein said anti-CD154 antibody comprises the Vt, complementarity determining regions (CDRs) of SEQ ID NO: 17, 18, and 19 and the VII CDRs of SEQ ID NO: 24, 25 and 26; wherein the additional Fc modification which impairs FcR binding is selected from the following mutations: E233P, D265A, D265N, D270N, N297A, S298N, P329A, D270A, K326V, V369R, F405K, L410P, V427R, L234N, G237M, S239F, V262E, V264F, V266T, S267N, N268E, N297R, T299A, R301D, N325L, N325E and L328R, and the additional Fc modification which impairs complement binding is a P331G or P331G/K322A mutation.

### Claim 29 (depends on 28)

A composition comprising the anti-CD154 antibody of claim 28 and a pharmaceutically acceptable carrier.

### Claim 30 (depends on 28)

A nucleic acid encoding an anti-CD154 antibody of the human IgG1 isotype according to claim 28, which comprises an Fc region which comprises an E269R mutation and a K322A mutation and which further comprises one additional Fc modification which impairs FcR binding and/or impairs complement binding, wherein said anti-CD154 antibody comprises the VL complementarity determining regions (CDRs) of SEQ ID NO: 17, 18, and 19 and the VH CDRs of SEQ ID NO: 24, 25 and 26 wherein the one additional Fc modification which impairs FcR binding is selected from the following mutations: E233P, D265A, D265N, D270N, N297A, S298N, P329A, D270A, K326V, V369R, F405K, L410P, V427R, L234N, G237M, S239F, V262E, V264F, V266T, S267N, N268E, N297R, T299A, R301D, N325L, N325E and L328R, and the additional Fc modification which impairs complement binding comprises a P331G or P331G/K322A mutation.

### Claim 31 (depends on 30)

An expression vector comprising the nucleic acid of claim 30 operably linked to a promoter.

### Claim 32 (depends on 30)

A recombinant cell comprising the nucleic acid of claim 30 operably linked to a promoter.

### Claim 33 (depends on 30)

A method of producing an anti-CD154 antibody of the human IgG1 isotype, which comprises an Fc region which comprises an E269R mutation and a K322A mutation, comprising culturing a cell comprising the nucleic acid of claim 30 operably linked to a promoter under conditions that permit expression of the anti-CD154 antibody encoded by said nucleic acid.

### Claim 34

The method of 33, which comprises isolating the expressed anti-CD154 antibody from the cell or culture medium comprising the cell.

### Claim 35

A method of obtaining an antibody that comprises an antigen binding region (ABD) which binds to a desired antigen and which comprises impaired FcR binding and complement binding by:
(i) obtaining an isolated nucleic acid that encodes for said ABD and a nucleic acid encoding an IgG1 Fc region of the human IgG1 isotype comprising an E269R mutation and a K322A mutation, wherein said isolated nucleic acids may be on the same or different nucleic acid constructs;
(ii) introducing said isolated nucleic acids into an isolated host cell;
(iii) culturing said host cell under conditions which provide for the expression of an antibody that comprises an antigen binding region (ABD) which binds to said desired antigen and which comprises an IgG1 Fc region of the human IgG1 isotype comprising an E269R mutation and a K322A mutation that comprises impaired FcR binding and complement binding; and
(iv) optionally isolating the resultant expressed antibody from the host cell or culture containing the host cell.

### Claim 36 (depends on 35)

The method of claim 35, wherein the desired antigen is human CD154.

### Claim 37 (depends on 35)

The method of claim 35, wherein the encoded IgG1 Fc region further comprises an additional Fc modification which impairs FcR binding and/or an additional Fc modification which impairs complement binding, wherein said additional Fc modification which impairs FcR binding is selected from the following mutations: E233P, D265A, D265N, D270N, N297A, S298N, P329A, D270A, K326V, V369R, F405K, L410P, V427R, L234N, G237M, S239F, V262E, V264F, V266T, S267N, N268E, N297R, T299A, R301D, N325L, N325E and L328R, and wherein said additional Fc modification which impairs complement binding is a P331G or a P331G/K322A mutation.
